Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method

Journal of Clinical Oncology

Volumn 24, Issue 27, 2006, Pages 4426-4433

  Normolle, Daniel ^a   Lawrence, Theodore ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG OVERDOSE; DRUG TOXICITY; HUMAN; MAXIMUM TOLERATED DOSE; MONTE CARLO METHOD; PRIORITY JOURNAL; RISK ASSESSMENT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALGORITHM; BAYES THEOREM; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; METHODOLOGY; NEOPLASM; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; STANDARD;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE I; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MONTE CARLO METHOD; NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN;

EID: 33749063821     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.3844     Document Type: Article

References (15)

1. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48, 1990
2. O'Quigley J: Another look at two phase I clinical trial designs. Stat Med 18:2683-2690, 1999
3. Piantadosi S, Fisher J, Grossman S: Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 41:429-436, 1998
4. Goodman S, Zahurak M, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995
5. Cheung K, Chappell R: Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177-1182, 2000
6. Simon R, Friedlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
7. Storer B: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
8. Babb J, Rogatko A, Zacks S: Cancer phase I clinical trials: Efficient dose escalation with overdose control. Stat Med 17:1103-1130, 1998
9. Leung D, Wang Y: Isotonic designs for phase I trials. Control Clin Trials 22:126-138, 2001
10. Thall P, Lee S: Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity. Int J Gynecol Cancer 13:251-261, 2003
11. Korn E, Midthune D, Chen T, et al: A comparison of two phase I trial designs. Stat Med 13:1799-1806, 1994
12. Muller J, McGinn C, Normolle D, et al: A phase I trial using the time-to-event continual reassessment strategy to escalate cisplatin with gemcitabine and radiation therapy for pancreatic cancer. J Clin Oncol 22:238-243, 2004
13. Eisenhauer E, O'Dwyer P, Christian M, et al: Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692, 2000
14. McGinn C, Zalupski M, Shureiqi I, et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001
15. Akerley W, Glantz M, Choy H, et al: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16:153-158, 1998